Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341403 | 0.80 | — | — | |
| SCHEMBL24630648 | 0.78 | EIF4A3 (0.31) | EIF4A3 | |
| SCHEMBL24943917 | 0.78 | EIF4A3 (0.56) | EIF4A3 | |
| SCHEMBL17811240 | 0.74 | KIF11 (0.44) | KDM4EALDH1A1HPGD | |
| SCHEMBL12755281 | 0.73 | DAO (0.49) | ALDH1A1 | |
| SCHEMBL17584904 | 0.70 | TNF (0.44) | — | |
| SCHEMBL12755294 | 0.70 | KDM4E (0.47) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL10212114 | 0.68 | CA2 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL20993192 | 0.68 | HRH4 (0.39) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12755307 | 0.67 | SCD (0.39) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | EIF4A3 3067/4885KDM4E 3164/4885ALDH1A1 4171/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | EIF4A3 3467/4885KDM4E 2224/4885ALDH1A1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.